|
|||||
|
|
Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events |
|
| Authors: | Heike C. Hawerkamp,Andreas Kislat,Peter A. Gerber,Marius Pollet,Katharina M. Rolfes,Anatoly A. Soshilov,Michael S. Denison,Afaque A. Momin,Stefan T. Arold,Angeliki Datsi,Stephan A. Braun,P ter Ol h,Mario E. Lacouture,Jean Krutmann,Thomas Haarmann‐Stemmann,Bernhard Homey,Stephan Meller |
| Affiliation: | Heike C. Hawerkamp,Andreas Kislat,Peter A. Gerber,Marius Pollet,Katharina M. Rolfes,Anatoly A. Soshilov,Michael S. Denison,Afaque A. Momin,Stefan T. Arold,Angeliki Datsi,Stephan A. Braun,Péter Oláh,Mario E. Lacouture,Jean Krutmann,Thomas Haarmann‐Stemmann,Bernhard Homey,Stephan Meller |
| Abstract: | |
| Keywords: | aryl hydrocarbon receptor drug eruption lymphocyte activation test melanoma vemurafenib |